Jonathan Hirsch
About Jonathan Hirsch
Jonathan Hirsch is the co-founder of Syapse, known for his pivotal role in advancing cancer care through precision medicine and real world evidence, and serves on several advisory boards.
Jonathan Hirsch: Co-Founder and Board of Advisors Chair at Syapse
Jonathan Hirsch co-founded Syapse in 2008, where he currently serves as the Chair of the Board of Advisors. At Syapse, Jonathan defined and implemented a vision focused on transforming cancer care through precision medicine and real world evidence. His leadership has been integral in advancing the company's mission and impact in the healthcare industry.
Jonathan Hirsch's Role in Cancer Care Innovation
Jonathan Hirsch has played a crucial role in the innovation of cancer care by leveraging precision medicine and real world evidence. His efforts have not only shaped the strategic direction of Syapse but also influenced broader industry standards. This includes his work in catalyzing national cancer data sharing networks and his involvement in the White House Cancer Moonshot Data Sharing Working Group.
Jonathan Hirsch's Involvement with Advisory Boards
Jonathan Hirsch serves on the Advisory Boards of several leading companies in the healthcare and technology sectors including Freenome, VizAI, and PaigeAI. His advisory roles leverage his extensive experience in the field to guide these companies in their strategic decision-making processes and the development of innovative solutions.
Jonathan Hirsch's Collaboration with the FDA
Jonathan Hirsch has significantly contributed to the regulatory use of real world evidence in healthcare. He created and served as the Principal Investigator for a Research Collaboration with the FDA. This initiative has helped shape how real world evidence is utilized for regulatory purposes, thereby impacting policy and practice in the healthcare industry.
Jonathan Hirsch's Investments and Venture Fund Partnerships
Jonathan Hirsch is also an active investor and partner in various venture funds, including the Kleiner Perkins seed fund and Rebel Fund. He has incubated and invested in numerous companies that operate at the intersection of healthcare and technology. His investment activities highlight his commitment to fostering innovation and supporting emerging companies in these sectors.